Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.487 USD | -2.60% | -0.49% | +73.87% |
Valuation
Fiscal Period: März | 2023 | 2024 | 2025 |
---|---|---|---|
Capitalization 1 | 18.02 | 36.7 | - |
Enterprise Value (EV) 1 | 18.02 | 36.7 | 36.7 |
P/E ratio | -1.54 x | -2.21 x | -3.04 x |
Yield | - | - | - |
Capitalization / Revenue | - | 29.5 x | 26.2 x |
EV / Revenue | - | 29.5 x | 26.2 x |
EV / EBITDA | - | - | - |
EV / FCF | - | - | - |
FCF Yield | - | - | - |
Price to Book | - | 4.43 x | -24.4 x |
Nbr of stocks (in thousands) | 53,077 | 75,365 | - |
Reference price 2 | 0.3395 | 0.4870 | 0.4870 |
Announcement Date | 7/7/23 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2023 | 2024 | 2025 |
---|---|---|---|
Net sales 1 | - | 1.243 | 1.399 |
EBITDA | - | - | - |
EBIT 1 | - | -10.31 | -10.36 |
Operating Margin | - | -829.61% | -740.6% |
Earnings before Tax (EBT) 1 | - | -12.8 | -10.53 |
Net income 1 | -11.51 | -12.8 | -10.53 |
Net margin | - | -1,030.09% | -752.75% |
EPS 2 | -0.2200 | -0.2200 | -0.1600 |
Free Cash Flow | - | - | - |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 7/7/23 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
---|---|---|---|---|---|---|
Net sales 1 | 0.204 | 0.193 | 0.622 | 0.329 | 0.231 | 0.218 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -2.998 | -2.684 | -2.427 | -2.603 | -2.662 | -2.669 |
Operating Margin | -1,469.61% | -1,390.67% | -390.19% | -791.19% | -1,152.38% | -1,224.31% |
Earnings before Tax (EBT) 1 | -5.589 | -2.689 | -2.47 | -2.645 | -2.704 | -2.712 |
Net income 1 | -5.589 | -2.689 | -2.47 | -2.645 | -2.704 | -2.712 |
Net margin | -2,739.71% | -1,393.26% | -397.11% | -803.95% | -1,170.56% | -1,244.04% |
EPS 2 | -0.0900 | -0.0400 | -0.0400 | -0.0400 | -0.0400 | -0.0400 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 2/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: March | 2023 | 2024 | 2025 |
---|---|---|---|
Net Debt | - | - | - |
Net Cash position | - | - | - |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | - | - |
ROE (net income / shareholders' equity) | - | - | - |
ROA (Net income/ Total Assets) | - | - | - |
Assets 1 | - | - | - |
Book Value Per Share 2 | - | 0.1100 | -0.0200 |
Cash Flow per Share | - | - | - |
Capex 1 | - | 0.19 | 0.27 |
Capex / Sales | - | 15.37% | 19.44% |
Announcement Date | 7/7/23 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.87% | 36.7M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IGC Stock
- Financials IGC Pharma, Inc.